BIO vs CDNA: fair value comparison
Bio-Rad Laboratories, Inc. and CareDx, Inc. · Updated 2026-09-13
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, BIO currently sits closer to the top of our discount ranking.
| BIO | CDNA | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $380.96 | $48.97 |
| 12-month range | $256.55–$380.96 | $14.77–$48.97 |
| Sector rank | #105 of 113 Healthcare | #107 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIO fair value analysis · CDNA fair value analysis